LA JOLLA, Calif., March 13, 2017 /PRNewswire/ -- DermTech, Inc., the global leader in non-invasive molecular dermatology, announced today the presentation of four studies at the 75th Annual Meeting of the American Academy of Dermatology in Orlando, Florida March 3-5, 2017. The four abstracts highlight the diverse dermatologic applications for DermTech's platform technology and included adhesive patch biopsy and gene expression utility in psoriasis, pediatric melanoma and microbiome studies.
Dr. Gerald G. Krueger, a leading expert in psoriasis research and treatment from the Department of Dermatology, University of Utah School of Medicine, presented an exciting study from on "Non-Invasive Gene Expression Analysis Assay for Psoriasis," which describes a robust yet non-invasive gene expression assay that is useful to predict disease flare-ups, monitor the condition at the gene expression level and potentially differentiate between responders and non-responders to aid physicians in their drug treatment decisions for psoriasis. The assay is based on gene expression analyses using very small amounts of RNA extracted from lesional and non-lesional epidermal skin through a robust non-invasive process.
Dr. Burkhard Jansen, Chief Medical Officer at DermTech, presented "Gene Expression Analysis Differentiates Pediatric Melanomas from Spitz Nevi," a study which demonstrated that gene expression analyses can be valuable objective aids to differentiate pediatric melanomas from Spitz nevi, a group of pigmented lesions mimicking melanoma, that can be particularly difficult to assess morphologically. This study expands on recent validation results.
Dr. Zuxu Yao, Chief Scientific Officer at DermTech, presented results on a study entitled "An Adhesive Patch-Based Skin Biopsy Device for Non-Invasive Gene Expression Analysis in Dermatology", which summarizes utility and applications of DermTech's gene expression platform technology not only as a tool for dermatologists, but also as a platform currently used by a number of pharmaceutical and large biotech companies to streamline their development of novel biologics and other targeted drug candidates in a variety of indications including psoriasis, atopic dermatitis, lupus, alopecia areata and vitiligo.
The skin microbiome is another important factor that contributes to skin health and disease pathophysiology. DermTech also presented a poster on "An Adhesive Patch Device for Skin Microbiome Studies", which highlights additional applications of the described non-invasive adhesive patch skin sampling device.
These studies demonstrate that DermTech's adhesive patch-based skin sample collection device is an easy to use, safe and robust method to non-invasively collect epidermal tissue samples for molecular analyses in dermatology. Samples collected via the adhesive patch method are stable and can be shipped cost effectively to analysis laboratories at ambient temperature avoiding the need for special storage and handling.
DermTech is the global leader in molecular dermatology. We market and develop non-invasive gene expression tests to aid the clinical diagnosis of skin cancer, assess inflammatory diseases, and to personalize drug treatment. DermTech's technology allows the analysis of skin biopsy samples collected non- invasively using an adhesive patch. Our mission is to transform dermatology by delivering highly accurate, objective information to physicians to improve care and reduce costs. For additional information visit: www.dermtech.com.
Sarah Dion, MBA
VP, Sales and Marketing
SOURCE DermTech, Inc.